Convection-enhanced delivery of Nimustine Hydrochloride combined with oral Temozolomide after surgical resection of recurrent malignant gliomas at first recurrence / Phase I/II study - ACNU/CED plus oral TMZ after surgical resection of recurrent malignant gliomas at first recurrence

Department of Neurosurgery, Tohoku University Graduate School of Medicine0 个研究点目标入组 20 人开始时间: 2013年8月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Co-existence of uncured cancer. 2) Co-existence of meningitis or pneumonia that require treatment. 3) Women in pregnancy or possibly pregnant women or breast feeding women 4) Severe liver dysfunction (GOT>100 IU/l or GPT>100 IU/l) 5) Existence of bone marrow insufficiency: WBC(<2,000/mm3), Hb (<8.0 g/dl), Plt(<10x104/mm3) 6) Renal dysfunction: Cre (>1.5 mg/dl) 7) Existence of hemorrhagic diathesis 8) Patients taking anti-coagulants or anti-platelet agents. 9) Existence of mental disorder that makes participation to this study difficult. 10) Poor control of diabetes mellitus 11) Past history of acute myocardial infarction within 3 months or unstable angina. 12) Past history of pulmonary fibrosis or interstitial pneumoniae.

发起方

Department of Neurosurgery, Tohoku University Graduate School of Medicine